IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

RUSCONI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.999
EU - Europa 22.505
AS - Asia 19.427
SA - Sud America 2.234
AF - Africa 885
OC - Oceania 145
Continente sconosciuto - Info sul continente non disponibili 27
Totale 68.222
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.997
GB - Regno Unito 6.184
CN - Cina 5.720
SG - Singapore 5.626
IT - Italia 5.485
DE - Germania 2.679
BR - Brasile 1.672
HK - Hong Kong 1.672
RU - Federazione Russa 1.618
VN - Vietnam 1.536
SE - Svezia 1.444
FR - Francia 1.088
BD - Bangladesh 1.071
IN - India 966
NL - Olanda 780
IE - Irlanda 725
CA - Canada 724
FI - Finlandia 663
KR - Corea 598
TR - Turchia 565
ID - Indonesia 438
UA - Ucraina 401
ES - Italia 344
JP - Giappone 342
MX - Messico 177
AR - Argentina 168
CI - Costa d'Avorio 168
BE - Belgio 165
EU - Europa 162
PL - Polonia 155
ZA - Sudafrica 155
CO - Colombia 149
DK - Danimarca 140
AU - Australia 130
CH - Svizzera 114
AT - Austria 113
PH - Filippine 107
TH - Thailandia 98
TW - Taiwan 97
IQ - Iraq 95
GR - Grecia 88
PK - Pakistan 69
EC - Ecuador 59
RO - Romania 58
CL - Cile 57
KE - Kenya 56
PT - Portogallo 56
SA - Arabia Saudita 55
UG - Uganda 54
ET - Etiopia 52
GH - Ghana 50
NG - Nigeria 50
IR - Iran 46
MA - Marocco 46
MY - Malesia 43
VE - Venezuela 40
NO - Norvegia 39
UZ - Uzbekistan 38
IL - Israele 36
PE - Perù 32
EG - Egitto 31
NP - Nepal 30
JO - Giordania 29
TN - Tunisia 25
AE - Emirati Arabi Uniti 24
CM - Camerun 23
JM - Giamaica 23
PY - Paraguay 23
CZ - Repubblica Ceca 20
DZ - Algeria 18
TZ - Tanzania 18
ZM - Zambia 17
CR - Costa Rica 16
HU - Ungheria 16
UY - Uruguay 16
KZ - Kazakistan 15
LT - Lituania 15
TG - Togo 15
BG - Bulgaria 14
NZ - Nuova Zelanda 14
OM - Oman 14
AZ - Azerbaigian 13
PA - Panama 13
LU - Lussemburgo 12
RS - Serbia 12
AL - Albania 11
BO - Bolivia 11
DO - Repubblica Dominicana 10
MK - Macedonia 10
AM - Armenia 9
KG - Kirghizistan 9
LB - Libano 9
MZ - Mozambico 9
A2 - ???statistics.table.value.countryCode.A2??? 8
BW - Botswana 8
EE - Estonia 8
HN - Honduras 8
MD - Moldavia 8
SL - Sierra Leone 8
BY - Bielorussia 7
Totale 68.154
Salva come PNG Salva come JPEG
Città #
Southend 5.313
Singapore 3.132
Ashburn 2.231
Hong Kong 1.427
Chandler 1.390
Milan 1.291
Fairfield 1.287
San Jose 1.225
Frankfurt am Main 1.101
Seattle 986
Beijing 913
Council Bluffs 900
Dallas 846
Houston 825
Wilmington 772
Dublin 715
Woodbridge 643
Princeton 641
Ann Arbor 580
Los Angeles 558
Santa Clara 438
Ho Chi Minh City 436
Cambridge 435
Boardman 434
New York 433
Hefei 388
Helsinki 386
Hanoi 370
Lauterbourg 342
Rome 341
Toronto 333
Bengaluru 326
Jakarta 323
Redwood City 300
Dearborn 287
Buffalo 276
Guangzhou 271
Nanjing 260
Des Moines 250
Moscow 248
Shanghai 236
Redmond 219
Jacksonville 215
Seoul 198
The Dalles 196
Hanover 188
Mountain View 171
Tokyo 170
Phoenix 169
Abidjan 162
São Paulo 158
Columbus 140
Chicago 133
Munich 129
Sakarya 126
Istanbul 125
Ottawa 125
Cangzhou 119
London 113
Nuremberg 112
Brussels 111
Warsaw 108
Jinan 107
Shenyang 104
Tianjin 103
Naples 101
Mumbai 94
Somerville 94
Atlanta 85
Da Nang 85
Bogotá 82
Shenzhen 81
Serra 80
Turin 78
Washington 77
Boise 76
Silver Spring 76
San Diego 75
Berlin 74
Andover 73
Central District 72
Changsha 71
Hangzhou 68
Hebei 67
Taipei 66
Haiphong 65
Nanchang 62
Athens 60
Montreal 60
Bodio Lomnago 59
Dong Ket 59
Zhengzhou 59
Margão 58
Florence 57
Fuzhou 57
Valencia 56
Grafing 55
Vienna 55
Bologna 54
Genoa 54
Totale 39.835
Salva come PNG Salva come JPEG
Nome #
Mapping the human genetic architecture of COVID-19 1.142
Long term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV1-infected, virologically suppressed patients 811
Renal complications in HIV disease : between present and future 807
Indirect and Direct Effects of SARS-CoV-2 on Human Pancreatic Islets 663
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 580
Self-reported symptoms of SARS-CoV-2 infection in a non-hospitalized population : results from the large Italian web-based EPICOVID19 cross-sectional survey. (Preprint) 559
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 533
Immunogenicity and safety of SARS-CoV-2 mRNA vaccines in a cohort of patients with type 1 diabetes 449
Five years with dolutegravir plus lamivudine as a switch strategy : much more than a positive finding 440
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 413
Description of a "Trans-Saharan" strain of human T-Lymphotropic virus type 1 in West Africa 396
Efficacy and tolerability of multiple drug therapy in HIV-infected children 393
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial 373
The problem of renal function monitoring in patients treated with the novel antiretroviral drugs 368
Is the rate of virological failure to cART continuing to decline in recent calendar years? 357
Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region : outcome after treatment in recently infected individuals 354
Does syphilis increase the risk of HIV-RNA elevation >200 copies/mL in HIV positive patients under effective antiretroviral treatment? Data from the ICONA cohort 351
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference 348
Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA) 340
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir 336
30-day mortality in patients hospitalized with COVID-19 during the first wave of the Italian epidemic: a prospective cohort study 335
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens 331
Prevalence and risk determinants of HIV-1 and HIV-2 infections in pregnant women in Bissau 326
Failure to eradicate HIV despite fully successful HAART initiated in the first days of life 322
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 321
Gammaglutamyltranspeptidase (gamma-GT) levels before treatment are predictive of Tipranavir interruption in ART multiexperienced HIV-1-infected patients 319
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 319
Prevalence of HIV-1 resistant strains in recent seroconverters 314
Safety of statin therapy in HIV/hepatitis C virus-coinfected patients 314
Does GSS Still Maintain Relevance on HAART Outcome After the Introduction of Newest Active Antiretroviral Drugs? 48 Weeks Results 313
Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post_treatment hospitalisation status 311
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA) 310
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial 309
A novel methodology for large-scale phylogeny partition 309
Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study 307
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 306
Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting 305
Accumulation of drug-related mutations in HIV-1 genome and virus replicative capacity in multi-drug failure subjects 304
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients : results from a multicenter cohort study 303
Atazanavir-induced severe episodes of kidney stones in an HIV-1-infected subject characterized by a CYP3A poor metabolizer phenotype 302
Italian consensus statement on management of HIV-infected individuals with advanced disease naive to antiretroviral therapy 302
Overall tolerability of Integrase Inhibitors in clinical practice: results from a multicenter Italian cohort 302
In vitro efficacy of a non-conventional (folding) HIV-1 protease inhibitor without selection of resistance 299
Maraviroc intensification for HIV-1-positive immunological non-responders (INRs) despite virological suppression during HAART 296
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts : Data from the Icona Foundation Cohort 295
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 295
Vpr and HIV-1 disease progression : R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients 293
Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation 289
Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV : experience in a pediatric population 289
Analysis of protease inhibitor combinations in vitro : activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates 288
Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST 288
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 288
Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression : 48-week efficacy and safety results 285
Virological response and retention in care according to time of starting ART in Italy: Data from the Icona Foundation Study cohort 284
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 282
Genomic characterisation and phylogenetic analysis of SARS-COV-2 in Italy 281
Durability of INI-containing regimens after switching from PI-containing regimens : a single-centre cohort of drug-experienced HIV-infected subjects 280
Primary HIV infection features colonic damage and neutrophil inflammation yet containment of microbial translocation 278
Human immunodeficiency virus (HIV) phenotype and interleukin-2/ interleukin-10 ratio are associated markers of protection and progression in HIV infection 277
Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection 276
New macrocyclic amines showing activity as HIV entry inhibitors against wild type and multi-drug resistant viruses 272
The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated : results from a prospective study 271
PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response 269
Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study 267
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 267
Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection : in vitro studies of mixed virus infections 263
Enhancing care for people living with HIV: current and future monitoring approaches 261
Susceptibility to a non-conventional (folding) protease inhibitor of human immunodeficiency virus type 1 isolates in vitro 260
Clinical pharmacology in HIV cure research : what impact have we seen? 260
Favorable therapeutic response with an antiretroviral salvage regimen in an HIV-1-positive subject infected with a CRF11-cpx virus 258
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 257
Differences in the prevalence of SARS-COV-2 infection and access to care between italians and non-italians in a social-housing neighbourhood of Milan, Italy 257
Epidemiological spread of drug-resistant HIV-1 strains 255
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study 253
Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A. : a modelling study 253
Human-to-Cat SARS-CoV-2 Transmission: Case Report and Full-Genome Sequencing from an Infected Pet and Its Owner in Northern Italy 251
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART 249
Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study 249
Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study 248
Efficacy of Maraviroc (MVC) as intensification strategy in immunological non-responder (INR) HIV-1-infected patients treated with HAART 245
Unusual codon 69 insertions : influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility 244
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 244
Incidence of hypertension and blood pressure changes in persons with HIV at high risk for cardiovascular disease switching from boosted protease inhibitors to dolutegravir: a post-hoc analysis of the 96-week randomised NEAT-022 trial 242
Kinetics of CD169, HLA-DR, and CD64 expression as predictive biomarkers of SARS-CoV2 outcome 242
Clinical and genetic determinants of nevirapine plasma trough concentration 242
96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day vs triple therapy in patients with suppressed viraemia: virological success and non-HIV related morbidity evaluation 242
The non-conventional (folding) protease inhibitor blocks the human immunodeficiency virus type-1 replication without evidence of resistance during in vitro passage 240
Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase I 239
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy : 48-Week results of a randomized trial 239
Absence of new thymidine-associated mutations and evidence of an immune virologic response over a 12-month period in a cohort of antiretroviral- experienced HIV-1-infected subjects treated with tenofovir combination therapy [2] 238
Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferation 235
Self-reported Olfactory and Taste Disorders in Patients with Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study 235
Analysis of the env V3 sequences obtained from patients with HIV type 1 infection treated with the immune modulant agent tucaresol 233
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection 233
Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine 229
Discontinuation of initial antiretroviral therapy in clinical practice : Moving toward individualized therapy 228
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients 227
Disappearance of cryoglobulins and remission of symptoms in a patient with HCV-associated type II mixed cryoglobulinemia after HIV-1 infection 226
Unveiling the basis of antiretroviral therapy-induced osteopenia: the effects of Dolutegravir, Darunavir and Atazanavir on osteogenesis 226
Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen : a retrospective cohort study 225
Totale 31.934
Salva come PNG Salva come JPEG
Categoria #
all - tutte 191.741
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 191.741
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021370 0 0 0 0 0 0 0 0 0 0 0 370
2021/20224.886 379 333 266 267 339 280 356 489 590 474 290 823
2022/20235.957 658 553 491 660 584 1.034 216 369 698 142 332 220
2023/20245.041 241 362 256 333 863 492 390 328 210 361 534 671
2024/202510.018 465 1.010 332 953 703 578 541 1.018 614 917 955 1.932
2025/202622.486 1.905 1.530 2.191 1.750 1.997 1.652 2.955 1.201 2.295 1.680 2.804 526
Totale 70.941